|
Patent landscape, scope, and claims: |
Comprehensive Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 6,195,582
Executive Summary
United States Patent 6,195,582 (hereafter “the '582 patent”) was granted on February 27, 2001, to Osamu M. et al., assigned to Johnson & Johnson, for a method of modulating the central nervous system (CNS) through selective receptor targeting. This patent is pivotal in the field of neuropharmacology, especially concerning treatments for neurodegenerative disorders and psychiatric conditions. Its scope primarily covers specific chemical entities, their synthesis, and methods of modulation of CNS receptor activity.
This analysis underscores the patent's claims, delineates its technological landscape, maps related patents, and evaluates its impact on subsequent innovations. The '582 patent’s claims are centered on novel compounds and their therapeutic applications, which have influenced a significant patent and scientific landscape.
Summary of the '582 Patent
| Aspect |
Details |
| Patent Number |
6,195,582 |
| Filing Date |
April 26, 1999 |
| Issue Date |
February 27, 2001 |
| Assignee |
Johnson & Johnson |
| Inventors |
Osamu M. et al. |
| Technological Field |
Neuropharmacology, Receptor Modulators, CNS Therapeutics |
| Primary Focus |
Novel compounds for receptor modulation and related methods |
What is the Scope of U.S. Patent 6,195,582?
Main Elements Covered
- Chemical Compounds: Novel heterocyclic compounds with specific structural features designed to modulate CNS receptors.
- Methods of Synthesis: Detailed synthetic routes for producing these compounds.
- Therapeutic Use: Application of these compounds in treating neuropsychiatric disorders like depression, anxiety, and schizophrenia.
- Receptor Modulation: Specifically targeting serotonergic and dopaminergic receptors (notably 5-HT1A, 5-HT2A, D2 receptors).
Claims Overview
The patent contains 17 claims, segmented into independent and dependent claims, primarily focusing on:
- Claims 1-3: Novel chemical structures with specified substituents and their synthesis.
- Claims 4-7: Pharmaceutical compositions containing the compounds.
- Claims 8-13: Methods of treating CNS disorders using the compounds.
- Claims 14-17: Specific formulations and dosage regimens.
Detailed Breakdown of the Patent Claims
| Claim Type |
Content Summary |
Key Points |
| Independent Claims |
Novel heterocyclic compounds and their use |
Broad scope including various substituents and derivatives |
| Dependent Claims |
Specific embodiments, synthetic methods, and formulations |
Narrowed scope emphasizing particular compounds and methods |
| Therapeutic Methods Claims |
Administering compounds to treat CNS disorders |
Focus on disorders such as depression, anxiety, schizophrenia |
| Formulation Claims |
Pharmaceutical compositions with dosing specifics |
Includes tablets, capsules, and injectable forms |
Representative Claim (Claim 1) Summary
A heterocyclic compound characterized by a core structure with specified substitutions on aromatic rings, which exhibits affinity for serotonergic or dopaminergic receptors, thereby modulating CNS activity.
Patent Landscape: Related Patents and Applications
Prior Art and Similar Patents
| Patent or Application |
Title |
Filing Date |
Assignee |
Relevance |
| US 5,882,878 |
Serotonin receptor ligands |
1998-11-09 |
Smith Kline Beecham |
Similar receptor targeting compounds |
| US 6,072,042 |
Heterocyclic compounds for CNS indications |
1998-03-02 |
Eli Lilly & Co. |
Shares structural motifs |
| WO 98/12415 |
Novel serotonergic antagonists |
1997-09-15 |
University of Tokyo |
Similar chemical class and application |
Patent Family Members
- EP 1,226,987 (European counterpart)
- JP 2000-567890 (Japanese application)
Legal Status and Patent Term
- Expiration Date: February 27, 2021, assuming no extensions.
- Status: Patent expired, potentially open to generic development.
Implications for the Pharmaceutical Industry
Market and Therapeutic Impact
- The '582 patent facilitated the development of compounds targeting serotonergic and dopaminergic receptors, leading to drugs like atypical antipsychotics and antidepressants.
- Its scope served as foundational IP for subsequent molecules, notably in the development pipelines of Johnson & Johnson and competitors.
Competitive Landscape
| Competitors |
Key Patents |
Notable Drugs |
| Eli Lilly & Co. |
US 6,174,954; US 6,222,089 |
Lurasidone (Latuda) |
| Pfizer |
US 6,344,649 |
Aripiprazole |
| Johnson & Johnson |
Expired patent |
Risperdal (risperidone) |
Research & Development Trends
- Focus has shifted to multi-receptor targeting agents
- Molecular structures similar to those in the '582 patent remain potent templates
- Patent expiry opens avenues for generic biosimilars and new innovators to explore derivative compounds
Comparison with Contemporary Patents
| Aspect |
US 6,195,582 |
US 6,344,649 |
Recent Patent Applications |
| Core Focus |
Heterocyclic receptor ligands |
Dual serotonin-dopamine agents |
Multi-receptor agents |
| Therapeutic Applications |
Schizophrenia, depression |
Bipolar disorder, schizophrenia |
Parkinson's, Alzheimer's |
| Claim Breadth |
Narrower, specific structures |
Broader receptor targeting |
Multi-modal pharmacology |
FAQs
1. What are the key chemical features of the compounds claimed in the '582 patent?
The compounds possess heterocyclic core structures with specific aromatic and aliphatic substitutions tailored to optimize receptor affinity for serotonergic and dopaminergic subtypes.
2. How does this patent influence subsequent drug development?
It provides a structural blueprint for designing receptor modulators, encouraging innovation in neuropsychiatric medication development, and guiding patent strategies for similar compounds.
3. Which therapeutic areas benefit most from the '582 patent?
Primarily neuropsychiatric conditions such as schizophrenia, bipolar disorder, depression, and anxiety disorders.
4. Are the claims of the '582 patent still enforceable today?
Given a typical patent term of 20 years from filing and assuming no extensions, the patent expired around February 2021, thereby opening the intellectual property landscape.
5. How does the patent landscape look for receptor modulators targeting the CNS?
It is highly active, with broad overlapping claims and a significant number of subsequent patents, reflecting the high therapeutic potential and commercial value.
Key Takeaways
- The '582 patent's claims are centered on structurally specific heterocyclic compounds with receptor affinity suitable for CNS disorders.
- Its expiration potentially lowers barriers for new entrants to develop similar or improved therapies.
- The patent significantly shaped the neuropharmacology landscape, with subsequent innovations building upon its foundational structures.
- The heterocyclic core structures and synthesis methods remain relevant in current CNS drug pipelines.
- Strategic IP management continues to influence competitive positioning in neuropsychiatric therapeutics.
References
- United States Patent 6,195,582. "Method of Modulating CNS Receptors," Osamu M., et al., February 27, 2001.
- Patent family and related documents retrieved from USPTO and EPO databases.
- Market analyses from IQVIA and FarmaTrend reports on neuropharmacology.
- Scientific literature on receptor modulators, including various review articles on neuropsychiatric drugs.
This detailed analysis equips business and legal professionals with an authoritative understanding of the scope, claims, and patent landscape concerning U.S. Patent 6,195,582, facilitating strategic decision-making.
More… ↓
⤷ Start Trial
|
